-
Natrecor: Medical Experts Adamant About Their Advice Given to Scios / Johnson & Johnson
Natrecor Advisory Panel Report is Probably Not What Drug Maker Expected, or Wanted In the August 9, 2005 edition of The New York Times, reporter Stephanie Saul succinctly characterized the current Natrecor situation: "Call…
-
MedEffect: The New Drug-safety Web Site from Health Canada
Intended to Collect Adverse Drug Reaction Information from, and for, Canadians On August 9, 2005 Health Canada launched "MedEffect", which is a new web site dedicated to collecting adverse drug reaction reports from Canadian…
-
Johnson & Johnson Attempts to Restrict Prescribing Of Heart-failure Drug Natrecor
Drug Company Warns Doctors Against "Off Label" Use of Natrecor at Clinics Johnson & Johnson is apparently acting on some two-month old advice from an expert panel of cardiologists in attempting to restrict the…
-
NEJM Publishes and Then, in the Same Edition, Challenges a Company-sponsored Study Article
A Classic Example of Medical Journal Manipulation by Pharmaceutical Industry? In the August 4, 2005 edition of the New England Journal Of Medicine, an editorial piece seems to cast some doubt on a research…
-
What Does Direct-to-Consumer Advertising Have to Do with Prescription Drug Clinical Trials?
Major Medical Journals Lead Us Astray by Publishing Studies Designed to Help Sell Product for the Drug Company Today, Richard Smith is Chief Executive of UnitedHealth Europe, in London. Previously, Mr. Smith was an…
-
FDA Chief Dr. Lester Crawford is Criticized on Drug-safety Issues
Vioxx Case Puts Spotlight on FDA’s Monitoring of Emerging Drug Side Effects At a July 26, 2005 hearing before a House of Representatives appropriations subcommittee, Dr. Lester Crawford, the new head of the FDA,…
